In short
Clinical trials are studying Triamcinolone Hexacetonide in people with juvenile idiopathic arthritis, rheumatoid arthritis, and carpal tunnel syndrome. These studies look at whether it helps improve disease control or treatment success, and they measure outcomes such as remission, symptom scores, and the need for surgery.
Key points
- Clinical trials of Triamcinolone Hexacetonide in this data focus on joint and nerve-related conditions, especially juvenile idiopathic arthritis, rheumatoid arthritis, and carpal tunnel syndrome. The studies are mostly Phase 3, with one Phase 4 study in early rheumatoid arthritis. Researchers are looking at outcomes such as remission, sustained inactive disease, symptom improvement, and treatment success. One trial compares joint injections added to TNF inhibitor treatment in children with juvenile idiopathic arthritis. Another study in carpal tunnel syndrome tests an injection-based strategy against surgery, and the rheumatoid arthritis study compares treatment approaches and de-escalation strategies.
Overview of the trial program
The trial data show three interventional studies of Triamcinolone Hexacetonide in different patient groups. The studies focus on juvenile idiopathic arthritis, carpal tunnel syndrome, and rheumatoid arthritis. Two trials are authorised and one is completed.
Juvenile idiopathic arthritis study
NCT04614311, called The My-JIA trial, is a Phase 3 study in children and young people with juvenile idiopathic arthritis. It enrolled 188 participants and is completed. The study asks whether adding intra-articular glucocorticoid injections, meaning steroid injections into the joint, to TNF inhibitor treatment helps more patients reach sustained inactive disease.
The main endpoint is the proportion of participants with sustained inactive disease according to the Wallace 2011 criteria and no intra-articular or oral glucocorticoid use from week 24 to week 36. In simple terms, the trial checks whether joint injections help children stay well for a longer time without needing more steroid treatment.
Carpal tunnel syndrome study
NCT05306548, called NOR-CACTUS, is a Phase 3 study in people with carpal tunnel syndrome. It is authorised and plans to include 258 participants. The study compares an injection-based strategy with ultrasound-guided injections, up to two injections, scheduled follow-up visits, and surgery if needed, against a strategy where surgery is the main treatment.
The primary outcome is successful treatment after one year, defined as a Boston Carpal Tunnel Questionnaire Symptom Score of 1.5 or lower. This means the study is testing whether starting with injections can work as well as surgery for improving symptoms over 12 months.
Rheumatoid arthritis study
NCT01491815 is a multicenter, randomized, open-label, blinded-assessor Phase 3 study in early rheumatoid arthritis. It is authorised and has an enrollment of 705 participants. The study compares active conventional therapy with three biologic treatments and also looks at two de-escalation strategies in people who respond to treatment.
De-escalation means reducing treatment after a person has responded well. Triamcinolone Hexacetonide appears in the treatment list as an intra-articular injection option in this study. The study is designed to see how many patients reach remission and how joint damage changes over time.
Main endpoints and outcome measures
Across the three studies, the main outcomes focus on disease control and treatment success. In juvenile idiopathic arthritis, the endpoint is sustained inactive disease without extra steroid use between weeks 24 and 36. In carpal tunnel syndrome, the endpoint is symptom score improvement at one year. In rheumatoid arthritis, the endpoints include remission at week 24 and progression of the Sharp van der Heijde score at 48 weeks, which tracks joint damage on X-ray.
Trial design, phases, and participants
All three studies are interventional trials, which means the researchers assign treatments and then measure what happens. The data include Phase 3 studies for juvenile idiopathic arthritis, carpal tunnel syndrome, and rheumatoid arthritis, plus one Phase 4 study in early rheumatoid arthritis. The target populations are children or young people with juvenile idiopathic arthritis, adults with carpal tunnel syndrome, and people with early rheumatoid arthritis.